Clinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI)

References

• StevensDLBisnoALChambersHFPractice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Disease Society of AmericaClin Infect Dis201459214715924947530
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug AdministrationGuidance for industry acute bacterial skin and skin structure infections: developing drugs for treatment2013 Available from: http://www.fda.gov/downloads/Drugs/Guidances/ucm071185.pdfAccessed April 6, 2016
   Google Scholar
• PallinDJEganDJPelletierAJIncreased US emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community-associated methicillin-resistant Staphylococcus aureusAnn Emerg Med20085129129918222564
   PubMed Web of Science ®Google Scholar
• WilderJRWegenerDTDavidMZA national survey of skin infections, care behaviors and MRSA knowledge in the United StatesPLoS One201498e10427725137061
   PubMed Web of Science ®Google Scholar
• DuongMMarkwellSPeterJRandomized, controlled trial of antibiotics in the management of community-acquired skin abscesses in the pediatric patientAnn Emerg Med20105540140719409657
   PubMed Web of Science ®Google Scholar
• HowdenBPDaviesJKJohnsonPDReduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implicationsClin Microbiol Rev20102319913920065327
   PubMed Web of Science ®Google Scholar
• ZhanelGGCalicDSchweizerFNew lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancinDrugs201070785988620426497
   PubMed Web of Science ®Google Scholar
• Dalvance™ [package insert]Chicago, ILDurata Therapeutics2014
   Google Scholar
• BaileyJSummersKMDalbavancin: a new lipoglycopeptide antibioticAm J Health Syst Pharm20086559961018359966
   PubMed Web of Science ®Google Scholar
• MalabarbaACiabattiRGlycopeptide derivativesCurr Med Chem200181759177311562292
   PubMed Web of Science ®Google Scholar
• MalabarbaAGoldsteinBPOrigin, structure and activity in vitro and in vivo of dalbavancinJ Antimicrob Chemother200555Suppl 2ii15ii2015750032
   PubMed Web of Science ®Google Scholar
• ChenAYZervosMJVazquezJADalbavancin: a novel antimicrobialInt J Clin Pract200761585386317362476
   PubMed Web of Science ®Google Scholar
• MarburyTDowellJASeltzerEPharmacokinetics of dalbavancin in patients with renal or hepatic impairmentJ Clin Pharmacol200949446547619318696
   PubMed Web of Science ®Google Scholar
• BuckwalterMDowellJAPopulation pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptideJ Clin Pharmacol2005451279128716239361
   PubMed Web of Science ®Google Scholar
• DorrMBJabesDCavaleriMHuman pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptideJ Antimicrob Chemother200555Suppl 2ii25ii3015750034
   PubMed Web of Science ®Google Scholar
• CavaleriMRivaSValagussaAPharmacokinetics and excretion of dalbavancin in the ratJ Antimicrob Chemother200555Suppl 2ii31ii3515750035
   PubMed Web of Science ®Google Scholar
• NicolauDSunHSeltzerEPharmacokinetics of dalbavancin in plasma and skin blister fluidJ Antimicrob Chemother20076068168417631507
   PubMed Web of Science ®Google Scholar
• StreitJMFritscheTRSaderHSJonesRNWorldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolatesDiagn Microbiol Infect Dis20044813714314972384
   PubMed Web of Science ®Google Scholar
• BowkerKENoelARMacGowanAPPharmacodynamics of dalbavancin studied in an in vitro pharmacokinetic systemJ Antimicrob Chemother20065880280516891629
   PubMed Web of Science ®Google Scholar
• AndesDCraigWAIn vivo pahramcodynamic activity of the glycopeptides dalbavancinAntimicrob Agents Chemother20075151633164217307987
   PubMed Web of Science ®Google Scholar
• CitronDMTyrellKLGoldsteinEJComparative in vitro activities of dalbavancin and seven comparator agents against 41 Staphylococcus species cultured from osteomyelitis infections and 18 VISA and hVISA strainsDiagn Microbiol Infect Dis20147943844024972854
   PubMed Web of Science ®Google Scholar
• FDA Briefing Document Anti-infective Advisory Committee Meeting – NDA 21-883: Dalvance (Dalbavancin) for injection3312014 Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM390792.pdfAccessed April 6, 2016
   Google Scholar
• GoldsteinEJCitronDMMerriamCVIn vitro activities of dalbavancin and nine comparator agents against anaerobic gram-positive species and CorynebacteriaAntimicrob Agents Chemother20034761968197112760876
   PubMed Web of Science ®Google Scholar
• LeuthnerKDYuenAMaoYRahbarADalbavancin (BI-387) for the treatment of complicated skin and skin structure infectionExpert Rev Anti Infect Ther201513214915925578881
   PubMed Web of Science ®Google Scholar
• JohnsonDMFritscheTRSaderHSJonesRNEvaluation of dalbavancin in combination with nine antimicrobial agents to detect enhanced or antagonistic interactionsInt J Antimicrob Agents20062755756016698238
   PubMed Web of Science ®Google Scholar
• LopezSHackbarthCRomanoGTriasJJabesDGoldsteinBPIn vitro antistaphylococcal activity of dalbavancin a novel glycopeptidesJ Antimicrob Chemother200555Suppl 2ii21ii2415750033
   PubMed Web of Science ®Google Scholar
• GoldsteinBPDraghiDCSheehanDJHoganPSahmDFBactericidal activity and resistance development profiling of dalbavancinAntimicrob Agents Chemother20075141150115417220411
   PubMed Web of Science ®Google Scholar
• JaureguiLEBabazadehSSeltzerERandomized, double-blind comparison of once-weekly versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infectionsClin Infect Dis2005411407141516231250
   PubMed Web of Science ®Google Scholar
• BoucherHWWilcoxMTalbotGHPuttaguntaSDasAFDunneMWOnce-weekly dalbavancin versus conventional therapy for skin infectionN Engl J Med2014370232169217924897082
   PubMed Web of Science ®Google Scholar
• DunneMWPuttaguntaSGiordanoPA randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infectionClin Infect Dis201662554555126611777
   PubMed Web of Science ®Google Scholar
• SeltzerEDorrMBGoldsteinBPOnce-weekly dalbavancin versus standard of care antimicrobial regiments for treatment of skin and soft tissue infectionsClin Infect Dis2003371298130314583862
   PubMed Web of Science ®Google Scholar
• DunneMWTalbotGHBoucherHWSafety of Dalbavancin in the treatment of skin and skin structure infections: a pooled analysis of randomized, comparative studiesDrug Saf201639214715726715497
   PubMed Web of Science ®Google Scholar